Senior Group Leader in Pathogen Dynamics, Nuffield Department of Medicine
I am a Senior Group Leader in Pathogen Dynamics at the Big Data Institute, and Professor in the Nuffield Department of Medicine. I am interested in studying the population dynamics and epidemiology of pathogens, and translating this knowledge to public health. The primary tools used in my group are mathematical modelling and pathogen genomics.
Trained in theoretical particle physics, I converted to mathematical biology after my PhD in 1998. I was Royal Society URF and then Professor in the Department of Infectious Disease Epidemiology at Imperial College before joining the BDI at Oxford in 2016.
Current topics of interest are: HIV virulence; HIV treatment as prevention; HIV genomics; pneumococcal genomics; antibiotic resistance; outbreak response; COVID-19 contact tracing apps, COVID-19 epidemic modelling, COVID-19 sequencing
COVID-19 work: www.coronavirus-fraser-group.org
Current projects: BEEHIVE is cross-European study of HIV genomics and virulence amongst seroconverters. HPTN071 PopART is a cluster-randomized trial of HIV prevention including universal test and treat, in a population of 1.2 million people at high risk in Zambia and South Africa. PANGEA is a consortium mapping HIV-1 genomic diversity and linking to prevention modelling across sub-Saharan Africa. AMPHEUS aims to deliver an integrated platform for clinical microbiology, real-time epidemiology and intervention research to fight infectious pathogens in low income settings. The goal of ARTIC is to build an outbreak response system from sample collection to public health dashboards. Since January 2020 we have been active in the response against COVID-19.
I lead a friendly group of currently nine postdocs at various stages of their careers, a software developer, a project officer and a scientific manager. We are recruiting postdocs at regular intervals and can supervise PhD students from several PhD programmes at Oxford University. Please don't hesitate to get in touch if you are interested in joining the group or collaborating with us.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil; an exploratory analysis of a randomised controlled trial
Clemens SC. et al, (2021)
OpenABM-Covid19-An agent-based model for non-pharmaceutical interventions against COVID-19 including contact tracing.
Hinch R. et al, (2021), PLoS Comput Biol, 17
The epidemiological impact of the NHS COVID-19 App.
Wymant C. et al, (2021), Nature
Cost and cost-effectiveness of a universal HIV testing and treatment intervention in Zambia and South Africa: evidence and projections from the HPTN 071 (PopART) trial
Thomas R. et al, (2021), The Lancet Global Health, 9, e668 - e680
SARS-CoV-2 within-host diversity and transmission
Lythgoe KA. et al, (2021), Science, 372, eabg0821 - eabg0821